60 Degrees (SXTP) news
Recent news
60 Degrees Pharmaceuticals plans January 2027 hospitalized babesiosis data readout; will seek pre-SNDA meeting with FDA
60 Degrees Pharmaceuticals Inc. has outlined plans to release data from its hospitalized babesiosis trial in January 2027, a key milestone in the company’s development pipeline. The firm also intends to request a pre-SNDA meeting (Supplemental New Drug Application) meeting with the U.S. Food and…
AInvest Wire · Oct 6, 202660 Degrees Pharmaceuticals - Target supplemental NDA submission March-April 2027 - SEC filing
AInvest Wire · Sep 14, 202660 Degrees Pharmaceuticals Q2 EPS USD -0.9
AInvest Wire · Aug 14, 202660 Degrees Pharmaceuticals Q2 operating expenses USD 2.33 million
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) reported decrease from $4.22 million recorded in the same period of 2024. The reduction in expenses was primarily attributed to absence of one-off charges that had impacted the 2024 quarter. Despite the decline in operating expenses, the…
AInvest Wire · Aug 14, 202660 Degrees Pharmaceuticals, Inc. announces private placement priced at-the-market under Nasdaq rules
60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) has announced a private placement offering priced at-the-market under Nasdaq rules, with the company seeking to raise up to $565,000 through the sale of common stock. The offering is conducted under an existing at-the-market (ATM) Sales Agreement with…
AInvest Wire · Jul 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.